AstraZeneca India FY26 Revenue ₹22,755.8 Mn, Up 33%; Reappoints Director, Appoints New Auditor
AstraZeneca India reported FY26 revenue of ₹22,755.8 million (₹2,275.58 crore), a 33% increase. The company approved the re-appointment of Ms. Shilpa Divekar Nirula as an Independent Director for a second 5-year term from December 29, 2026. M/s. BSR & Co. LLP was appointed as new Statutory Auditors. A dividend of ₹36 per share was recommended.
The significant revenue growth, dividend recommendation, re-appointment of a key director, and appointment of a new auditor are material events that can impact investor sentiment and the company's operational and financial future.
The company reported strong revenue growth of 33% and secured multiple regulatory approvals for new medicines and indications, indicating positive business performance and expansion.
AstraZeneca Pharma India Limited announced its audited financial results for the quarter and financial year ended March 31, 2026, on May 26, 2026. The company reported a total revenue of ₹22,755.8 million (₹2,275.58 crore) for FY2025-26, marking a 33% year-on-year growth. Profit before exceptional items and tax stood at ₹2,574.5 million (₹257.45 crore), and profit after exceptional items and tax was ₹1,875.2 million (₹187.52 crore).
The Board of Directors also approved the re-appointment of Ms. Shilpa Divekar Nirula as Non-Executive, Independent Director for a second term of 5 years, effective December 29, 2026, subject to shareholder approval. Additionally, M/s. BSR & Co. LLP was approved as the new Statutory Auditors for a term of five consecutive years, commencing from the conclusion of the 47th AGM until the 52nd AGM in 2031, replacing M/s. Price Waterhouse Cooper. The Board recommended a dividend of ₹36 per equity share for FY2025-26, subject to shareholder approval.
During FY2025-26, the company secured 11 regulatory approvals for medicines and indications, reinforcing its leadership across therapy areas. Key approvals included new indications for Durvalumab, Eculizumab for rare diseases, and Osimertinib. The company also received several recognitions, including 'Pharma Company of the Year' at ET RePharma Awards and 'Top Employer India 2025'. The board meeting commenced at 2:15 P.M. and concluded at 5:10 P.M. (IST).
What to do with a filing like this
AstraZeneca Pharma India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by AstraZeneca Pharma India Limited. Read the original for the full detail.